First in Human Study of YB1-X7 Injection

NANot yet recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

March 15, 2025

Primary Completion Date

January 31, 2027

Study Completion Date

March 31, 2027

Conditions

Advanced Solid Tumors

Interventions

DRUG

YB1-X7 Injection (IT)

Intratumoral injection

DRUG

YB1-X7 Injection (IV)

Intravenous infusion

All Listed Sponsors

lead

Shanghai Salvectors Biotechnology LTD.

INDUSTRY

NCT06889675 - First in Human Study of YB1-X7 Injection | Biotech Hunter | Biotech Hunter